Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Head-to-Head: which drug tames facial nerve pain better?

NCT ID NCT07252453

Symptom relief Sponsor: Abbasi Shaheed Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study compares carbamazepine and oxcarbazepine, two drugs used to treat trigeminal neuralgia, a condition causing severe facial pain. Researchers will enroll 122 adults aged 18-60 who have had the condition for at least two weeks. They will measure pain relief using a standard pain scale and track side effects like liver problems and dizziness.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
carbamazepine and oxcarbazepine
What this could lead to
If one drug works better or has fewer side effects, it could become the preferred first-choice treatment for trigeminal neuralgia pain.
What could go wrong
This is a small, single-center study comparing two already-approved drugs. The difference may be small, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

122 people

The number who actually took part.

Started

May 2025

Expected to finish

Dec 2025

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 60 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

* Inclusion Criteria: * Age 18-60 years * Either gender * TGN diagnosis for ≥2 weeks (according to ICHD-3 criteria¹) Exclusion Criteria \[Expanded\]: * Other cranial neuralgias * Prior surgical treatment for TN * Hepatic/renal dysfunction * Epilepsy * Pregnant/lactating women * Drug allergy or intolerance * \[Expanded\] Uncontrolled hypertension * \[Expanded\] Psychiatric disorders

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Trigeminal neuralgia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

trigeminal neuralgia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Trigeminal neuralgia

Contacts and locations

Locations

  • Abbassi Shaheed hospital Facio-Maxillary Department

    Karachi, Sindh, 75500, Pakistan

More trials for these conditions

Other studies related to the condition(s) this trial covers.